Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694057 | 0.87 | MGAM (0.31) | MGAM | |
| Hydrochloric Acid SCHEMBL5439273 | 0.86 | MGAM (0.30) | MGAM | |
| Bromide SCHEMBL5439308 | 0.86 | MGAM (0.30) | MGAM | |
| Hydrochloric Acid SCHEMBL28712022 | 0.79 | C5AR1 (0.40) | — | |
| SCHEMBL5691742 | 0.77 | — | — | |
| SCHEMBL5691744 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL5444912 | 0.74 | — | — | |
| Bromide SCHEMBL5445825 | 0.74 | — | — | |
| SCHEMBL14316383 | 0.73 | KMT2A (0.32) | — | |
| SCHEMBL19130279 | 0.69 | HRH3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060293526-A1 | Immobilised imidazoles and ruthenium catalysts | MERK PATENT GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
| EP-1654064-A2 | IMMOBILISED IMIDAZOLES AND RUTHENIUM CATALYSTS | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016524-A2 | IMMOBILISED IMIDAZOLES AND RUTHENIUM CATALYSTS | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293526-A1 | Immobilised imidazoles and ruthenium catalysts | PIN4, MIF, SCO2 | MGAM 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.